-
admin
Posts
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) —...
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris®...
CLOU’s BESS Tour: Empowering Renewable Latin America
SANTIAGO, Chile, March 21, 2025 /PRNewswire/ — The Energy Year Summit Chile kicked off on March 19th, 2025, in Santiago, Chile. On the second day...
Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up
SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) today announced its full-year results for the period ending December 31,...
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from...
Nexdata at Tech.AD Europe 2025: Hyperspeed Project Scaling with Next-Gen Data Solutions
BERLIN, March 21, 2025 /PRNewswire/ — In 2025, the automotive industry is embracing Visual Language Actions (VLAs) to enhance ADAS (Advanced Driver Assistance Systems) and...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained...
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) — The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a...
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2...
